Pharma Mar SA - Company Profile
Powered by 
All the data and insights you need on Pharma Mar SA in one report.
$295
- Save hours of research time and resources with
our up-to-date Pharma Mar SA Strategy Report
- Understand Pharma Mar SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Pharma Mar SA (Pharma Mar) discovers, develops, manufactures, and commercializes products of marine-derived drugs for the treatment of cancer. The company operates through three reportable segments including, Oncology, Diagnostic and RNAi.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D focuses on discovery and development of new antitumor compounds of marine origin for the treatment of cancer. The company’s pipeline products include lurbinectedin in Phase III clinical trials indicated for the treatment of mesothelioma. It is also developing Zepzelca (lurbinectedin) in combination with irinotecan under the brand name LAGOON as second-line treatment for relapsed small cell lung cancer in Phase III trials for the treatment of small cell lung cancer. Phase III trial of IMforte was conducted by its partner Jazz Pharmaceuticals to assess Zepzelca in combination with Tecentriq, a PD-L1 inhibitor, for treating small cell lung cancer is also advancing satisfactorily. PM14 in Phase I/II clinical trials for the treatment of solid tumors and soft tissue sarcoma; Tivanisiran in Phase III for dry eye disease and SYL1801 in Phase II trials for the treatment of macular degeneration. It is also developing RNAi technology formulations and modifications in Preclinical phase for delivery optimization. It operates Virology unit to discover, develop new therapeutic tools for viral diseases and SARS-CoV-2. In line with this, the company is developing plitidepsin, a potent antiviral agent for patients with COVID-19. In FY2022, the company spent EUR83.4 million on its R&D, which as a percentage of revenue stood at 42.5% and increased 15.5% YoY.
Business Segments
Overview
Develops and markets diagnostic kits through its subsidiaries: Genomica SAU and its subsidiaries: Genomica AB and Genomica Trading Co Ltd. Offers laboratory equipment including autoclart, an equipment used for automation of post-PCR process. Its products include diagnostic kits used for detection of human papilloma virus, virus that cause respiratory infections, enteroviruses, human herpes virus. It also offers kits for in vitro diagnosis of Influenza A and B, and respiratory syncytial virus.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Discovers, develops and market anti-tumor drugs through subsidiaries: Pharma Mar SA, Pharma Mar USA, PharmaMar AG, Pharma Mar SARL, Pharma Mar GmbH, Pharma Mar Ltd, Pharma Mar SrL, Pharma Mar Sprl and Pharma Mar Ges mbHAT. Offers Yondelis (trabectedin), an antitumour agent of marine origin approved in the North America, South America, Europe and Asia for the treatment of soft tissue sarcoma and relapsed ovarian cancer in combination with doxorubicin HCl liposome injection in European Union; Zepzelca (lurbinectedin), an analog the marine compound ET-736 approved in US FDA for the treatment of adults with small cell lung cancer; Aplidin (Plitidepsin), an anticancer agent of marine origin approved in Australia and received Orphan Drug Designation in the European Union and the US for the treatment of multiple myeloma.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Develops drugs with therapeutic activity based on reducing or silencing gene expression through its subsidiary, Sylentis SAU.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward